Intraindividual variability in neuropsychological performance predicts longitudinal cortical volume loss in early Parkinson's disease.


Journal

Neuropsychology
ISSN: 1931-1559
Titre abrégé: Neuropsychology
Pays: United States
ID NLM: 8904467

Informations de publication

Date de publication:
Sep 2022
Historique:
pubmed: 5 4 2022
medline: 23 8 2022
entrez: 4 4 2022
Statut: ppublish

Résumé

Cognitive impairment is common among individuals with Parkinson's disease (PD). Intraindividual variability (IIV) is a measure of variability across multiple tasks of cognitive functioning. Due to the limited amount of research, particularly among individuals with PD, IIV has been an underutilized metric of cognitive functioning both in research and clinical practice. Previous research demonstrated that individuals with PD have greater variability in cognitive performance relative to controls, and that IIV is predictive of future cognitive impairments. The aim of this study is to investigate the association between baseline IIV and change in cortical and subcortical volumes among individuals with PD. The present study used data from 80 newly diagnosed PD patients who were part of a longitudinal cohort study (Parkinson progression marker initiative [PPMI]). Participants completed neuropsychological measures and underwent T1 structural magnetic resonance imaging (MRI) at baseline and the first annual follow-up. Neuropsychological tests assessed attention, processing speed, visuospatial functioning, verbal fluency learning, and memory. T1 scans were processed using standard Freesurfer protocols for extraction of regional volumes. Greater IIV at baseline was predictive of change in cortical volume in posterior temporal/parietal regions over the 1-year period. Baseline IIV predicted cortical volume changes above and beyond the main effect of motor severity and the baseline statistical mean/global cognition score. Our results provide initial evidence that IIV is a marker of longitudinal cortical volume loss. Evidence is building that IIV is a sensitive marker of cognitive impairment and the underlying neurodegeneration among individuals with PD. (PsycInfo Database Record (c) 2022 APA, all rights reserved).

Identifiants

pubmed: 35377683
pii: 2022-48130-001
doi: 10.1037/neu0000809
pmc: PMC9620776
mid: NIHMS1843233
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

513-519

Subventions

Organisme : NINDS NIH HHS
ID : SC3 NS124906
Pays : United States
Organisme : NIH HHS
Pays : United States

Références

Neuropsychology. 2018 Feb;32(2):206-212
pubmed: 28891655
J Clin Neurosci. 2018 Nov;57:116-120
pubmed: 30150061
J Neurol Neurosurg Psychiatry. 2012 Feb;83(2):188-94
pubmed: 21890574
Eur J Neurol. 2008 Feb;15(2):128-33
pubmed: 18217883
Brain. 2003 Nov;126(Pt 11):2363-80
pubmed: 12876148
Neurobiol Dis. 2020 Jun;139:104831
pubmed: 32145376
PLoS One. 2011 Apr 19;6(4):e16973
pubmed: 21526188
J Clin Exp Neuropsychol. 2006 Jan;28(1):67-83
pubmed: 16448976
J Parkinsons Dis. 2015;5(3):569-74
pubmed: 26406137
Neuropsychologia. 2007 Jun 18;45(11):2499-507
pubmed: 17507058
Brain. 2018 May 1;141(5):1501-1516
pubmed: 29701787
Mov Disord. 2020 Nov;35(11):1987-1998
pubmed: 32886420
Prog Neurobiol. 2011 Dec;95(4):629-35
pubmed: 21930184
Front Hum Neurosci. 2019 Oct 15;13:352
pubmed: 31680907
Parkinsonism Relat Disord. 2013 Oct;19(10):864-8; discussion 864
pubmed: 23746454
Neuropsychologia. 2012 Feb;50(3):357-66
pubmed: 22172547
Acta Neuropathol. 2008 Apr;115(4):427-36
pubmed: 18273624
Lancet Neurol. 2010 Dec;9(12):1200-1213
pubmed: 20880750
Neuropsychology. 2018 Nov;32(8):966-972
pubmed: 30211610
Brain Cogn. 2004 Dec;56(3):320-7
pubmed: 15522770
Assessment. 1999 Jun;6(2):147-78
pubmed: 10335019
J Neurol Neurosurg Psychiatry. 2013 Nov;84(11):1258-64
pubmed: 23781007
Psychol Aging. 2009 Dec;24(4):792-808
pubmed: 20025396
Drug Alcohol Depend. 2017 Jan 01;170:120-127
pubmed: 27889592
Neuropsychology. 2020 Jan;34(1):24-30
pubmed: 31219297
J Neurol Neurosurg Psychiatry. 2019 Nov;90(11):1251-1256
pubmed: 31175168
J Gerontol B Psychol Sci Soc Sci. 2017 Dec 15;73(1):87-99
pubmed: 29029333
Mov Disord. 2008 Apr 30;23(6):837-44
pubmed: 18307261
J Cogn Neurosci. 2009 Feb;21(2):289-302
pubmed: 18564054
Neurology. 2010 Sep 21;75(12):1062-9
pubmed: 20855849
Brain Imaging Behav. 2016 Sep;10(3):640-51
pubmed: 26303224
Neuropsychology. 2011 Sep;25(5):645-54
pubmed: 21574712
Neuroimage. 2012 Aug 15;62(2):774-81
pubmed: 22248573

Auteurs

Yenny G Valenzuela (YG)

Department of Psychology.

Carmen Uribe (C)

Department of Psychology.

Joseph Bunch (J)

Department of Psychology.

Taylor P Kuhn (TP)

Department of Psychiatry and Biobehavioral Sciences.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH